ERBB2 and neoplasm: Further research, including those using preclinical models that express abnormally high copies of ERBB2ΔEx16 and those analyzing the AFs for the ΔEx16 allele from circulating tumor cells, may unravel the significance of concurrent ERBB2 amplification and exon 16 skipping in conferring TKI resistance.